US › Healthcare

Cartesian Therapeutics Inc. (RNAC)

US · Healthcare · Biotechnology

$7.86-0.63%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$13.7M

Profit YoY

-13.6%

EPS

$0.46

EPS estimate

$-0.83

EPS came in at 0.46 against a street estimate of -0.83 — a beat of 155.4%.

Key statistics

Market cap

$238.7M

Forward P/E

25.1

P/B

31.26

Book value

$-4.17

EPS (TTM)

$-5.67

52-week high

$11.00

52-week low

$5.60

50-day MA

$8.83

200-day MA

$7.71

Beta

0.62

Analyst view

Analysts rate Cartesian Therapeutics Inc. a buy (6 buy, 2 hold, 0 sell out of 8) with an average price target of $34.57.

Shareholding

Insiders

52.13%

Institutions

29.45%

Largest institutional holders

Fund	Stake
Squarepoint Ops LLC	7.40%
FMR Inc	2.64%
BlackRock Inc	1.98%
Vanguard Capital Management, LLC	1.35%
683 Capital Management LLC	1.09%
Millennium Management LLC	1.02%
Two Sigma Investments LLC	0.98%
Geode Capital Management, LLC	0.87%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cartesian Therapeutics Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.